Welcome to our dedicated page for TENAX THERAPEUTICS SEC filings (Ticker: TENX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tenax Therapeutics filings document a Phase 3, development-stage pharmaceutical company developing cardiopulmonary therapies, including TNX-103 (oral levosimendan) for PH-HFpEF. Recent 8-K reports record financial results, clinical program updates for LEVEL and LEVEL-2, intellectual-property notices, and amendments to levosimendan license rights, including expanded worldwide rights for orally administered products.
Proxy and current-report filings also describe Nasdaq-listed common stock, executive appointments, employment and compensation arrangements, equity awards, governance matters, and named-executive pay disclosures. These records frame the company's capital structure, leadership responsibilities, material agreements, and clinical-stage operations around levosimendan development and commercialization rights.
TENAX THERAPEUTICS, INC. (TENX) received a Schedule 13G reporting a significant ownership position by Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander. These reporting persons disclose beneficial ownership of 2,156,891 shares of Tenax Therapeutics common stock, representing 5.8% of the outstanding class. They report no sole voting or dispositive power over the shares, but shared voting and shared dispositive power over the same 2,156,891 shares. The shares are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers that may be controlled by Millennium Group Management LLC and Mr. Englander. The filing states that this structure should not, by itself, be construed as an admission by any of the reporting persons of beneficial ownership of the securities held by those entities.
Ikarian Capital, LLC and Neil Shahrestani report beneficial ownership of Tenax Therapeutics, Inc. common stock on a passive basis. They report beneficial ownership of 1,080,700 shares of common stock, including 373,100 shares that may be acquired within 60 days through options. Based on 37,423,917 shares outstanding as of July 28, 2026, their reported ownership represents 2.9% of Tenax’s common stock. Voting and dispositive power over these shares is reported on a shared basis through a Cayman Islands fund and certain separately managed accounts advised by Ikarian Capital. The reporting persons expressly disclaim being part of a group or being beneficial owners beyond what may be deemed under Section 13(d) or 13(g).
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. report beneficial ownership of 1,700,000 shares of Tenax Therapeutics, Inc. common stock. The Master Fund holds the shares directly, while Perceptive Advisors (as investment manager) and Mr. Edelman (as managing member) may be deemed beneficial owners.
The shares are reported with shared voting and dispositive power among the reporting persons. Ownership calculations reference 37,423,917 Tenax common shares outstanding as of July 28, 2026, as disclosed in the company’s quarterly report.
Tenax Therapeutics, Inc. is reported to be beneficially owned by a group of Venrock Healthcare Capital entities and individuals Nimish Shah and Bong Koh, who together hold rights to acquire 1,574,892 shares of common stock as of June 30, 2026. This represents 4.7% of Tenax’s common stock, calculated against 31,949,785 shares outstanding plus the shares issuable from the warrants. The position is held entirely through pre-funded warrants and common warrants across several Venrock-related funds and management entities, with all voting and dispositive powers reported on a shared basis and no sole voting or dispositive power. The group indicates ownership of 5 percent or less of the class.
Tenax Therapeutics, Inc. has an updated Schedule 13G/A from Biotechnology Value Fund and affiliated funds and entities reporting beneficial ownership of its common stock. As of June 30, 2026, these reporting persons and a managed account held pre-funded warrants exercisable for 7,698,531 shares of common stock at an exercise price of $0.01 per share and an additional 3,970,596 warrants that are immediately exercisable but currently blocked from exercise by a 9.99% ownership cap.
Due to the “Pre-Funded Warrants Blocker” and “Warrants Blocker,” only 2,770,814 shares underlying the pre-funded warrants are currently counted toward beneficial ownership. On this basis, BVF beneficially owned 2,966,661 shares, and BVF Partners L.P., BVF Inc., and Mark N. Lampert may each be deemed to beneficially own 3,110,363 shares, or approximately 9.99% of the outstanding shares, with various entities in the BVF complex sharing voting and dispositive power.
Tenax Therapeutics, Inc. is reported as having a significant shareholder group led by Vivo Opportunity Fund Holdings, L.P. and its general partner, Vivo Opportunity, LLC. These reporting persons together beneficially own 3,458,327 Tenax securities, consisting of 2,500,000 shares of common stock and pre-funded warrants to purchase 958,327 additional common shares. Based on 37,423,917 shares of common stock outstanding as of July 28, 2026, plus the shares underlying the pre-funded warrants, this position represents 9.0% of Tenax’s common stock. The reporting persons have sole voting and dispositive power over all 3,458,327 securities, and no shared voting or dispositive power.
RTW Investments, LP and Roderick Wong, M.D. report beneficial ownership of Tenax Therapeutics, Inc. Common Stock. They report beneficial ownership of 2,866,654 shares, representing 9.99% of the class, with shared voting and dispositive power and no sole voting or dispositive power. This percentage is calculated based on 26,525,159 shares outstanding as of May 8, 2026 and assumes the exercise of RTW-held warrants to purchase 2,170,084 shares, subject to a 9.99% beneficial ownership limitation. The RTW Funds, including RTW Master Fund Ltd., have the right to receive dividends and sale proceeds for these shares, while the filing states it should not be construed as an admission that any reporting person is the beneficial owner for all purposes.
Adage Capital Management, L.P. and related parties report beneficial ownership of Tenax Therapeutics, Inc. common stock. The group, consisting of Adage Capital Management, L.P., and individuals Robert Atchinson and Phillip Gross, reports beneficial ownership of 1,899,495 shares of common stock, including 1,359,369 shares issuable upon exercise of warrants held by Adage Capital Partners, L.P. This position represents 6.81% of Tenax’s common stock, based on 26,525,159 shares outstanding as of May 8, 2026, and assuming exercise of the warrants. Voting and dispositive powers over these shares are reported on a shared basis, with no sole voting or dispositive power indicated for any reporting person.
Tenax Therapeutics reported topline Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in patients with pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF). The study randomized 241 patients 1:1 to TNX-103 or placebo across 41 sites in the United States and Canada.
The trial did not meet its primary endpoint of improvement in 6-minute walk distance at Week 12, with a treatment difference of 3.5 meters (p=0.63), nor the key secondary endpoint in Kansas City Cardiomyopathy Questionnaire total symptom score. Prespecified exploratory analyses showed a 49% reduction in NT-proBNP versus placebo (nominal p<0.0001) and a 3.5 mmHg reduction in right ventricular systolic pressure (nominal p=0.0045). A prespecified subgroup with baseline 6-minute walk distance below 333 meters had a 26.3-meter benefit versus placebo (95% CI 6.0, 46.7; nominal p=0.0112). TNX-103 was generally safe and well tolerated, with serious adverse events and adjudicated clinical worsening events balanced across arms. Tenax plans to request a Type C meeting with the FDA and parallel EMA consultation to refine its Phase 3 development plan and enrichment strategy for TNX-103.
Christopher Thomas Giordano, President and Chief Executive Officer of Tenax Therapeutics, reports beneficial ownership of 1,690,606 shares of common stock, representing 4.32% of the class. This consists of 11,324 shares of common stock and 1,679,282 shares underlying stock options.
He holds sole voting and dispositive power over these shares. The percentage is based on 37,423,917 shares of common stock outstanding as of July 28, 2026. The amendment is filed solely as a result of an increase in the number of issued and outstanding shares and is described as the final amendment and an exit filing for the reporting person.